Age‐Related Macular Degeneration Market Epidemiology Report 2025-2035: Pipeline Analysis, Treatment, Trends, Rising Incidence & Prevelance

The age-related macular degeneration market size reached a value of USD 10.3 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 12.2 Billion by 2035, exhibiting a growth rate (CAGR) of 1.61% during 2025-2035.

The Age‐Related Macular Degeneration (AMD) market is the category of products, treatments, diagnostic equipment, and support services intended to assist individuals with this prevalent cause of blindness in older people. AMD generally impacts the macula, the part of the retina that handles precise vision. As people live longer and become more informed, the AMD market has grown steadily, guided by new drugs, diagnostic technology, and changing demographics.

An increased penchant for teletherapy and online platforms is closing urban-rural care gaps and lowering the cost of treatment. Such platforms are increasing user trust and attracting capital investment. Care models involving collaboration between schools, families, and healthcare professionals are on the rise. This integrated approach positions ASD care as part of larger educational and community systems, improving consistency of care.

Request for a sample of this report: https://www.imarcgroup.com/age-related-macular-degeneration-market/requestsample

By 2025, the AMD market has moved beyond simple anti-VEGF injections to novel therapies, digital diagnostics, and personalized care models. The market today encompasses three broad categories: diagnostic solutions, treatment options, and post‐treatment support services. Diagnostics consist of advanced retinal imaging and genetic testing. Treatment options vary from established injections to novel gene and stem cell therapies. Support services cover low‐vision aids and telehealth platforms for continuous monitoring.

Market Growth Drivers

The AMD market grows worldwide in 2025, stimulated by a range of important factors. To begin with, the aging population in developed and emerging markets is growing greatly and thereby raising demand. As individuals live longer, patient numbers are gradually rising, driving market growth. Second, improved technology in retinal imaging and home‐based monitoring equipment is facilitating earlier and more precise diagnosis, thus stimulating treatment adoption. Third, more positive healthcare policies and improved insurance coverage for sight‐saving procedures are increasing the availability of treatments. Overall, these forces are supporting consistent year‐on‐year market size growth.

Recent Trends Influencing the Market

One key trend is the movement toward longer‐acting therapies. New formulations of medications and extended release implants seek to decrease the number of eye injections, enhancing patient comfort and adherence. Early experiments with gene and stem cell therapies also are making waves, promising more long‐lasting treatment effects and even reversal of disease. A second trend is an increase in digital diagnostics, such as AI‐enabled retinal scans and mobile vision apps that track changes from afar, allowing patients to be treated without regular visits to clinics. Also on the rise are tele‐ophthalmology and virtual follow‐up care, which make specialty treatment available to older adults living in remote or underserved communities.

Technological Advancements

Diagnostic imaging has been transformed through optical coherence tomography (OCT), which gives precise cross‐sectional views of the retina. Handheld OCT machines and smartphone‐based retinal cameras are now on the market, enabling routine monitoring at home and enhancing early detection. In therapeutic innovation, gene therapies for genetic forms of AMD are moving through clinical trials, and stem cell therapies for regenerating compromised retinal cells are in the works. Digitally, apps and wearable sensors are designed to quantify visual performance and medication compliance in real time, linking patients with care providers using secure telehealth platforms.

Ask the Analyst for Customization and Get Full Insights with TOC: https://www.imarcgroup.com/request?type=report&id=7911&flag=E

Challenges and Opportunities

As promising as new therapy is, the market for AMD has challenges. Painful and costly gene and stem cell therapies' clinical trials and high development expenses can slow approval and raise costs. Patient compliance is still a challenge, with repeated office visits for injection potentially cumbersome for older adults. Nevertheless, challenges offer opportunities. Investors in long-acting treatments, home-friendly monitoring devices, and virtual care platforms will position themselves well to address market needs and enhance patient outcomes.

The report also provides a detailed analysis of the current age-related macular degeneration marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Competitive Landscape:

The competitive landscape of the age-related macular degeneration market has been studied in the report with the detailed profiles of the key players operating in the market.

Novartis AG
Genentech USA, Inc.
Bayer AG
Neuraclegenetics
OliX Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Sanofi

IMARC Group Offers Other Reports:

Malignant Mesothelioma Market https://www.imarcgroup.com/malignant-mesothelioma-market

Post-Partum Depression Market https://www.imarcgroup.com/post-partum-depression-market

Heart Failure Market https://www.imarcgroup.com/heart-failure-market

Acute Lymphoblastic Leukemia Market https://www.imarcgroup.com/acute-lymphoblastic-leukemia-market

Nonmelanoma Skin Cancer market https://www.imarcgroup.com/nonmelanoma-skin-cancer-market

Bacterial Vaginosis Market https://www.imarcgroup.com/bacterial-vaginosis-market

Chronic Lymphocytic Leukemia Market https://www.imarcgroup.com/chronic-lymphocytic-leukemia-market

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.